Search Results - haiyong+peng

2 Results Sort By:
Targeted Anti-ROR2 Antibodies for Precision Cancer Therapy
Enables Selective Targeting of ROR2-Positive Tumors Using High-Affinity Antibodies and Antibody-Drug Conjugates These targeted anti-ROR2 antibodies enable precision cancer therapy by selectively engaging ROR2-positive tumors with high-affinity antibodies and antibody-drug conjugates (ADCs). The ADC market is projected to grow from $13.5 billion to...
Published: 5/18/2026   |   Updated: 5/18/2026   |   Inventor(s): Christoph Rader, Xiuling Li, Haiyong Peng
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Diagnostics, Technology Classifications > Human Health Care > Therapeutics
Potentiating Antibody Therapy by Targeting Complement Deposited on Cancer Cells
Monoclonal antibodies (mAbs) have become a mainstay of therapy for many cancers. However, antibody therapy is not completely effective in some applications due to loss of the target surface antigen on cancer cells. Such mAb-induced “escape variants” are no longer sensitive to the therapeutic mAb therapy. It was observed that the escape variants carried...
Published: 10/28/2024   |   Updated: 12/6/2022   |   Inventor(s): Martin Skarzynski, Margaret Lindorfer, Ronald Taylor, Christoph Rader, Berengere Vire, Erika Gaglione, Haiyong Peng, Sivasubramanian Baskar, Adrian Wiestner
Keywords(s): 2JXXXX, 4GXXXX, 5OXXXX, ANTIBODY, C3, C3d, CANCER, CB1XXX, Cell, Cells, Complement, Deposited, Listed LPM Vathyam as of 4/15/2015, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Potentiating, Pre LPM working set 20150418, Protein, Surface, Targeting, THERAPY, THEROF, VCXXXX
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology